Fig. 4
6G influences the VEGF/VEGFR2 signaling pathway and targeting of VEGFR2. a Gene oncology and KEGG enrichment analysis of 6G-treated and control HUVECs. Enrichment analysis of differentially expressed proteins revealed associations with the extracellular structure organization, blood vessel morphogenesis, actin filament bundle organization and assembly. Pathway analysis of 6G-affected proteins showed that 6G targeted the VEGFa/VEGFR2 pathway. b Positive pull-down assay confirming the binding of 6G with VEGFR2 but not with VEGFR1. **, P < 0.01, one-way ANOVA. c Microscale thermophoresis (MST) assay showing the binding of 6G to VEGFR2. d Surface plasma resonance assay confirming the interaction between 6G and VEGFR2. 6G targeted VEGFR2 with favorable binding results. e Molecular docking of 6G binding into the active site of VEGF/VEGFR2 complex. 6G forms one key hydrogen bond with VEGFa and two hydrogen bonds with VEGFR2. f Effect of 6G on p-VEGFR2, p-PI3k and p-AKT in HUVECs. Results were obtained from three independent experiments, each performed in triplicate, and the error bars represent SD (*P < 0.05, **P < 0.01)